Literature DB >> 6702874

Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia.

J P Sculier, J Klastersky.   

Abstract

Serum bactericidal activity was determined routinely in 89 patients with gram-negative bacillary bacteremia, 79 of whom were analyzed because they had granulocyte counts either below 100/mm3 or above 1,000/mm3. A peak (one hour after the administration of the antibiotics) serum bactericidal titer of 1:8 or more in non-granulocytopenic patients or 1:16 or more in severely granulocytopenic patients could be correlated with a favorable clinical response, in 98 percent (44 of 45) (p less than 0.0001) and 87 percent (20 of 23), (p less than 0.001) respectively. Granulocytopenic patients required a statistically significantly higher serum bactericidal activity for a favorable response. Serum bactericidal activity appears to be a useful and simple method to monitor antibiotic treatment in gram-negative bacillary bacteremia, especially when combination therapy is used.

Entities:  

Mesh:

Year:  1984        PMID: 6702874     DOI: 10.1016/0002-9343(84)90662-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  52 in total

Review 1.  Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

Authors:  M A Pfaller; D J Sheehan; J H Rex
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 2.  Current concepts in laboratory testing to guide antimicrobial therapy.

Authors:  Stephen G Jenkins; Audrey N Schuetz
Journal:  Mayo Clin Proc       Date:  2012-03       Impact factor: 7.616

3.  Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole.

Authors:  M Boeckh; H Lode; K M Deppermann; S Grineisen; F Shokry; R Held; K Wernicke; P Koeppe; J Wagner; C Krasemann
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

Review 4.  Empiric treatment of infection during granulocytopenia: a comprehensive approach.

Authors:  J Klastersky
Journal:  Infection       Date:  1989 Mar-Apr       Impact factor: 3.553

5.  Serum bactericidal activity and killing rate for volunteers receiving imipenem, imipenem plus amikacin, and ceftazidime plus amikacin against Pseudomonas aeruginosa.

Authors:  P Van der Auwera; J Klastersky; H Lagast; M Husson
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

6.  Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults.

Authors:  M Tod; O Lortholary; D Seytre; R Semaoun; B Uzzan; L Guillevin; P Casassus; O Petitjean
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

7.  Comparative serum bactericidal activities of three doses of ciprofloxacin administered intravenously.

Authors:  M Dan; F Poch; C Quassem; R Kitzes
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 8.  Cefonicid. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  E Saltiel; R N Brogden
Journal:  Drugs       Date:  1986-09       Impact factor: 9.546

9.  Double beta-lactam regimen compared to an aminoglycoside/beta-lactam regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients.

Authors:  J H Joshi; K A Newman; B W Brown; R S Finley; R L Ruxer; M A Moody; S C Schimpff
Journal:  Support Care Cancer       Date:  1993-07       Impact factor: 3.603

10.  Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients.

Authors:  J Klastersky; M P Glauser; S C Schimpff; S H Zinner; H Gaya
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.